Related Experiment Videos

Beta-blockers for hypertension: are they going out of style?

Qi Che1, Martin J Schreiber, Mohammed A Rafey

  • 1Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Cleveland Clinic Journal of Medicine
|September 4, 2009
PubMed

Insights

Beta-blockers effectively lower blood pressure but show disappointing results in hypertension trials. Their use should be limited to patients with specific cardiac conditions or resistant hypertension.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Hypertension Research

Background:

  • Beta-blockers are commonly prescribed for hypertension.
  • Clinical trials have yielded disappointing outcomes for beta-blocker antihypertensive therapy.
  • The efficacy of beta-blockers in patients without specific indications is debated.

Purpose of the Study:

  • To evaluate the clinical utility of beta-blockers in hypertension management.
  • To determine the appropriate patient populations for beta-blocker therapy in hypertension.

Main Methods:

  • Review of clinical hypertension trials involving beta-blockers.
  • Analysis of patient outcomes based on indications for beta-blocker use.

Main Results:

  • Hypertension trials with beta-blockers have shown suboptimal results.
  • The benefit of beta-blockers is questionable in patients lacking compelling indications.
  • Beta-blockers demonstrated value in specific cardiac patient groups.

Conclusions:

  • Beta-blockers should be reserved for patients with compelling cardiac indications for hypertension treatment.
  • Consider beta-blockers as add-on therapy for uncontrolled or resistant hypertension.
  • Further evidence is needed to support broad use of beta-blockers in hypertension.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...